Clinical trial · Observational
Efficacy of Osimertinib in Patients With Lung Cancer
Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
NCT06174857CI-TRIAL-00072357unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- progression-free survival
- timeFrame
- 3 years
- description
- From registration onto that step until death, or censored at the date of last contact.
- measure
- Overall survival
- timeFrame
- 3 years
- description
- From registration onto that step until death, or censored at the date of last contact.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be ≥18 years. * Provision of fully informed consent prior to any study specific procedures. * Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology. * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.